Recommendations supporting respiratory syncytial virus vaccines marketed by Pfizer (NYSE:PFE) and GSK (NYSE:GSK) made last month by an advisory panel to the CDC are under review from a top advisor to ...

Pfizer is looking to follow its vaccine/oral antiviral combination that has proved so profitable in COVID-19 with a similar approach in respiratory syncytial virus (RSV). The drugmaker is in the ...

Of the RSV patients aged 60 or older, 23.0% were admitted to an ICU, 31.5% had acute organ failure, and 9.8% received IMV or ...

Pfizer has designed the virtual Annual Meeting ... for ABRYSVO®, the company’s bivalent respiratory syncytial virus (RSV) prefusion F (RSVpreF) vaccine, to extend the indication to include ...

The announcement, which followed the FDA setting new guidelines on COVID vaccine approvals, erased the stock’s gains from ...

The Pfizer Middle East, Russia and Africa (MERA) Maternal Immunization Summit: Born Ready brought together more than 80 medical experts, physicians, and healthcare professionals together in Cairo ...

An FDA panel of experts has recommended approval of Pfizer’s respiratory syncytial virus (RSV) vaccine in a pair of votes, neither of which was a resounding win. The Vaccines and Related ...

Pfizer (NYSE:PFE) is one of the world’s largest pharmaceutical companies, but at $22.59 per share as of this writing, the ...

Far fewer babies went to the hospital struggling to breathe from RSV, a severe respiratory infection, after the debut of a new vaccine and treatment this season, according to an analysis published ...

An aide to U.S. Health Secretary Robert F. Kennedy Jr. is seeking more information about three vaccines recommended by a ...